Informações:
Falhas:
ID
22425
Descrição
Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT00374699
Link
https://clinicaltrials.gov/show/NCT00374699
Palavras-chave
Versões (1)
- 02/06/2017 02/06/2017 -
Transferido a
2 de junho de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Peripheral T-Cell Lymphomas NCT00374699
Eligibility Peripheral T-Cell Lymphomas NCT00374699
- StudyEvent: Eligibility
Similar models
Eligibility Peripheral T-Cell Lymphomas NCT00374699
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Peripheral T-Cell Lymphoma | Lymphoma, Extranodal NK-T-Cell | Anaplastic large T-cell lymphoma Anaplastic lymphoma kinase Positive
Item
histologically confirmed ptcls and nk/t cell lymphomas excluding anaplastic lymphoma kinase (alk)-positive anaplastic large cell t-cell lymphomas (alcl)
boolean
C0079774 (UMLS CUI [1])
C1955906 (UMLS CUI [2])
C1275317 (UMLS CUI [3,1])
C0252409 (UMLS CUI [3,2])
C1514241 (UMLS CUI [3,3])
C1955906 (UMLS CUI [2])
C1275317 (UMLS CUI [3,1])
C0252409 (UMLS CUI [3,2])
C1514241 (UMLS CUI [3,3])
ECOG performance status
Item
performance status (ecog) ≤ 3
boolean
C1520224 (UMLS CUI [1])
Age
Item
age ≤ 65
boolean
C0001779 (UMLS CUI [1])
Measurable Disease Linear Quantity
Item
at least one or more unidimensionally measurable lesion(s)
boolean
C1513041 (UMLS CUI [1,1])
C0205132 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0205132 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Lesion size X-Ray Computed Tomography
Item
≥ 2 cm by conventional computed tomography (ct)
boolean
C0449453 (UMLS CUI [1,1])
C0040405 (UMLS CUI [1,2])
C0040405 (UMLS CUI [1,2])
Lesion size Spiral Computed Tomography
Item
≥ 1 cm by spiral ct
boolean
C0449453 (UMLS CUI [1,1])
C0860888 (UMLS CUI [1,2])
C0860888 (UMLS CUI [1,2])
Skin lesion Photograph
Item
skin lesion (photographs should be taken)
boolean
C0037284 (UMLS CUI [1,1])
C0441468 (UMLS CUI [1,2])
C0441468 (UMLS CUI [1,2])
Measurable Disease Physical Examination
Item
measurable lesion by physical examination
boolean
C1513041 (UMLS CUI [1,1])
C0031809 (UMLS CUI [1,2])
C0031809 (UMLS CUI [1,2])
Laboratory Results
Item
laboratory values
boolean
C1254595 (UMLS CUI [1])
Creatinine measurement, serum | Creatinine clearance measurement
Item
creatinine (cr) < 1.5 mg% or creatinine clearance (ccr) > 50 ml/min
boolean
C0201976 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
C0373595 (UMLS CUI [2])
Transaminases
Item
transaminase < 3 x upper normal value
boolean
C0002594 (UMLS CUI [1])
Serum total bilirubin measurement
Item
bilirubin < 2.0 mg/dl
boolean
C1278039 (UMLS CUI [1])
Absolute neutrophil count
Item
absolute neutrophil count (anc) > 1,500/ul
boolean
C0948762 (UMLS CUI [1])
Platelet Count measurement
Item
platelets > 75,000/ul
boolean
C0032181 (UMLS CUI [1])
Informed Consent
Item
informed consent
boolean
C0021430 (UMLS CUI [1])
Ann Arbor lymphoma staging system
Item
ann arbor stage iii or iv
boolean
C0432516 (UMLS CUI [1])
Malignant Neoplasms | Basal cell carcinoma | Carcinoma in situ of uterine cervix
Item
any other malignancies within the past 5 years except basal cell skin cancer or carcinoma in situ (cis) of the cervix
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0851140 (UMLS CUI [3])
C0007117 (UMLS CUI [2])
C0851140 (UMLS CUI [3])
Comorbidity Serious
Item
serious comorbid diseases
boolean
C0009488 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0205404 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
pregnancy or breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Study Subject Participation Status
Item
any waiver of these inclusion and exclusion criteria must be approved by the investigator and the sponsor on a case-by-case basis prior to enrolling the subject. this must be documented by both the sponsor and the investigator. no subject will be allowed to enroll in this study more than once.
boolean
C2348568 (UMLS CUI [1])